Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 17, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share transactions.
| Transaction Date | Instrument | Price | Volume |
|---|---|---|---|
| July 13, 2017 | Ordinary Shares (GBP) | £16.2250 | Various (194.930 to 487.325) |
| July 13, 2017 | American Depositary Shares (USD) | $42.4750 | 308.094 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine increases in notional interest in shares resulting from dividend reinvestment.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions reported are automatic reinvestments of dividends paid on July 13, 2017, under the Company's Deferred Investment Award Programme.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were increases in notional interest via dividend reinvestment, not open market purchases or sales.
- Participants: Transactions involved six executives, including CEO Emma Walmsley, President of Global Pharmaceuticals Salim Hussain, and President of R&D Peter Vallance.
- Share Prices: Ordinary Shares traded at £16.2250 and ADSs at $42.4750 on the transaction date.
- Scope: This filing is a regulatory disclosure of insider holdings changes and does not reflect broader company performance.